The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

The invention concerns a human interferon, designated PRO655, and its variants and derivatives. The interferon is related to but distinct from members of the IFN-.alpha. family and from IFNs-.beta. and -.gamma.. Nucleic acid encoding the polypeptide, and methods and means for their recombinant production are also included.

The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention….

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or cardiovascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds, various cancers, and disorders of the vessels including atherosclerosis and cardiac hypertrophy. In addition, th…

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

The invention concerns a novel human interferon-.epsilon., originally designated PRO655, and its variants and derivatives. The novel interferon is related to but distinct from members of the IFN-.alpha. family and from IFNs-.beta. and -.gamma.. Nucleic acid encoding the novel polypeptide, and methods and means for their recombinant production are also included.

The invention concerns a novel human interferon-.epsilon., originally designated PRO655, and its variants and derivatives. The novel interferon is related to but distinct from members of the IFN-.alpha. family and from IFNs-.beta. and -.gamma.. Nucleic acid encoding the novel polypeptide, and methods and means for their recombinant production are also included.

The invention concerns a human interferon-.epsilon., originally designated PRO655, and its variants and derivatives. The interferon is related to but distinct from members of the IFN-.alpha. family and from IFNs-.beta. and -.gamma.. Nucleic acid encoding the polpypeptide, and methods and means for their recombinant production are also included.

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.